FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of proliferative diseases. Pharmaceutical combination for the treatment of a malignant lung tumour, comprising (i) a MET tyrosine kinase inhibitor 2-fluoro-N-methyl-4-[(7-quinolin-6-ylmethyl)imidazo[1,2-b]triazin-2-yl]benzamide or a pharmaceutically acceptable salt thereof and (ii) an EGFR tyrosine kinase inhibitor gefitinib, and at least one pharmaceutically acceptable carrier; its use for the treatment of a malignant lung tumour, a method for treating a malignant lung tumour using this pharmaceutical combination (versions) and use of an inhibitor of EGFR gefitinib and a MET inhibitor 2-fluoro-N-methyl-4-[(7-quinolin-6-ylmethyl)-imidazo[1,2-b]triazin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical combination for the treatment of a malignant lung tumour.
EFFECT: technical result consists in the synergism of the action of the disclosed combination against a malignant lung tumour.
6 cl, 5 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY | 2015 |
|
RU2695230C2 |
| COMBINATION OF PIK3 INHIBITOR AND INHIBITOR C-MET | 2013 |
|
RU2705095C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2598852C2 |
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER | 2007 |
|
RU2452492C2 |
| PYRIDINE DERIVATIVES AS INHIBITORS OF VASCULAR ENDOTHELIUM GROWTH FACTOR RECEPTORS 2 (VEGFR-2) AND PROTEIN TYROSINE KINASE | 2009 |
|
RU2522444C2 |
| TYROSINE KINASE INHIBITORS | 2006 |
|
RU2408584C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS | 2006 |
|
RU2411242C2 |
| APPLICATION OF IMIDAZOQUINOLINES FOR TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH AQUIRED RESISTANCE TO AGENTS BINDING MEMBERS OF EGFR FAMILY | 2008 |
|
RU2481838C2 |
